Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 96 articles:
HTML format



Single Articles


    November 2022
  1. OLIVIER P, Giraudet AL, Skanjeti A, Merlin C, et al
    Phase III study of (18)F-PSMA-1007 versus (18)F-fluorocholine PET/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, cross-over, multicenter study.
    J Nucl Med. 2022 Nov 23:jnumed.122.264743. doi: 10.2967/jnumed.122.264743.
    PubMed     Abstract available


  2. DUAN H, Ghanouni P, Daniel B, Rosenberg J, et al
    A Pilot Study of (68)Ga-PSMA11 and (68)Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer.
    J Nucl Med. 2022 Nov 17. pii: jnumed.122.264448. doi: 10.2967/jnumed.122.264448.
    PubMed     Abstract available


  3. FRAGOSO COSTA P, Pullen L, Kesch C, Krafft U, et al
    F18-PSMA Cerenkov luminescence and flexible autoradiography Imaging in a prostate cancer mouse model and first results of a radical prostatectomy feasibility study in men.
    J Nucl Med. 2022 Nov 10. pii: jnumed.122.264670. doi: 10.2967/jnumed.122.264670.
    PubMed     Abstract available


  4. DUAN H, Ghanouni P, Daniel B, Rosenberg J, et al
    A Pilot Study of (68)Ga-PSMA11 and (68)Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy.
    J Nucl Med. 2022 Nov 3. pii: jnumed.122.264783. doi: 10.2967/jnumed.122.264783.
    PubMed     Abstract available


  5. WANG G, Zang J, Jiang Y, Liu Q, et al
    A single-arm, low-dose, prospective study of (177)Lu-EB-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer.
    J Nucl Med. 2022 Nov 3. pii: jnumed.122.264857. doi: 10.2967/jnumed.122.264857.
    PubMed     Abstract available


  6. JADVAR H, Abreu AL, Ballas LK, Quinn DI, et al
    Oligometastatic Prostate Cancer: Current Status and Future Challenges.
    J Nucl Med. 2022;63:1628-1635.
    PubMed     Abstract available


    October 2022
  7. COOK GJR, Wong WL, Sanghera B, Mangar S, et al
    Eligibility for (177)Lu-PSMA therapy depends on the choice of companion diagnostic tracer: a comparison of (68)Ga-PSMA-11 and (99m)Tc-MIP-1404 in metastatic castrate resistant prostate cancer.
    J Nucl Med. 2022 Oct 27. pii: jnumed.122.264296. doi: 10.2967/jnumed.122.264296.
    PubMed     Abstract available


  8. RAHBAR K, Essler M, Pabst KM, Eiber M, et al
    Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study.
    J Nucl Med. 2022 Oct 27. pii: jnumed.122.264456. doi: 10.2967/jnumed.122.264456.
    PubMed     Abstract available


  9. PHELPS TE, Harmon SA, Mena E, Lindenberg L, et al
    Predicting Outcomes of Indeterminate Bone Lesions on (18)F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer.
    J Nucl Med. 2022 Oct 20. pii: jnumed.122.264334. doi: 10.2967/jnumed.122.264334.
    PubMed     Abstract available


  10. SATHEKGE M, Bruchertseifer F, Vorster M, Lawal IO, et al
    mCRPC Patients Receiving (225)Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis.
    J Nucl Med. 2022;63:1496-1502.
    PubMed     Abstract available


    September 2022
  11. KARIMZADEH A, Heck M, Tauber R, Knorr K, et al
    (177)Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer: prognostic value of scintigraphic and clinical biomarkers.
    J Nucl Med. 2022 Sep 22. pii: jnumed.122.264402. doi: 10.2967/jnumed.122.264402.
    PubMed     Abstract available


  12. SCHOLLHAMMER R, Robert G, Asselineau J, Yacoub M, et al
    Comparison of (68)Ga-PSMA-617 PET/CT and (68)Ga-RM2 PET/CT in patients with localized prostate cancer candidate for radical prostatectomy: a prospective, single arm, single center, phase II study.
    J Nucl Med. 2022 Sep 2. pii: jnumed.122.263889. doi: 10.2967/jnumed.122.263889.
    PubMed     Abstract available


  13. BELLAVIA MC, Patel RB, Anderson CJ
    Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic.
    J Nucl Med. 2022 Sep 2. pii: jnumed.122.264373. doi: 10.2967/jnumed.122.264373.
    PubMed     Abstract available


  14. KLOSE JM, Wosniack J, Iking J, Staniszewska M, et al
    Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice.
    J Nucl Med. 2022;63:1357-1363.
    PubMed     Abstract available


  15. COSTA PF, Fendler WP, Herrmann K, Sandach P, et al
    Radiation Protection and Occupational Exposure on (68)Ga-PSMA-11-Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted Prostatectomy.
    J Nucl Med. 2022;63:1349-1356.
    PubMed     Abstract available


    August 2022
  16. HAGENS MJ, Oprea-Lager DE, Vis AN, Wondergem M, et al
    Reproducibility of PSMA PET/CT Imaging for primary staging of treatment-naive prostate cancer patients depends on the applied radiotracer: a retrospective study.
    J Nucl Med. 2022 Aug 25. pii: jnumed.121.263139. doi: 10.2967/jnumed.121.263139.
    PubMed     Abstract available


  17. BEYER T, Czernin J, Freudenberg LS, Giesel F, et al
    A 2022 INTERNATIONAL SURVEY ON THE STATUS OF PROSTATE CANCER THERANOSTICS.
    J Nucl Med. 2022 Aug 11. pii: jnumed.122.264298. doi: 10.2967/jnumed.122.264298.
    PubMed     Abstract available


    July 2022
  18. DERLIN T, Widjaja L, Werner RA, Bengel FM, et al
    (177)Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2022 Jul 19. pii: jnumed.122.264293. doi: 10.2967/jnumed.122.264293.
    PubMed     Abstract available


  19. KOEHLER D, Sauer M, Klutmann S, Apostolova I, et al
    Feasibility of (99m)Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients.
    J Nucl Med. 2022 Jul 14. pii: jnumed.122.263892. doi: 10.2967/jnumed.122.263892.
    PubMed     Abstract available


  20. HOFLING AA, Fotenos AF, Niu G, Fallah J, et al
    Prostate Cancer Theranostics: Concurrent Approvals by the Food and Drug Administration of the First Diagnostic Imaging Drug Indicated to Select Patients for a Paired Radioligand Therapeutic Drug.
    J Nucl Med. 2022 Jul 7. pii: jnumed.122.264299. doi: 10.2967/jnumed.122.264299.
    PubMed    


  21. PAINDELLI C, Casarin S, Wang F, Diaz-Gomez L, et al
    Enhancing (223)Ra Treatment Efficacy by Anti-beta1 Integrin Targeting.
    J Nucl Med. 2022;63:1039-1045.
    PubMed     Abstract available


    June 2022
  22. PATHMANANDAVEL S, Crumbaker M, Nguyen A, Yam AOW, et al
    The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with (177)LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
    J Nucl Med. 2022 Jun 23. pii: jnumed.122.264104. doi: 10.2967/jnumed.122.264104.
    PubMed     Abstract available


  23. SIEBINGA H, Olde Heuvel J, Rijkhorst EJ, Hendrikx JJMA, et al
    The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on (68)Ga-PSMA-11 PET/CT in Primary Prostate Cancer Patients.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264101. doi: 10.2967/jnumed.122.264101.
    PubMed     Abstract available


  24. POMYKALA KL, Herrmann K, Padhani AR, Hofman MS, et al
    Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Prostate Cancer: We have the answers.
    J Nucl Med. 2022 Jun 9. pii: jnumed.122.264394. doi: 10.2967/jnumed.122.264394.
    PubMed    


  25. SARTOR O, Herrmann K
    Prostate Cancer Treatment: (177)Lu-PSMA-617 Considerations, Concepts, and Limitations.
    J Nucl Med. 2022;63:823-829.
    PubMed     Abstract available


  26. JADVAR H
    The VISION Forward: Recognition and Implication of PSMA-/(18)F-FDG+ mCRPC.
    J Nucl Med. 2022;63:812-815.
    PubMed     Abstract available


    May 2022
  27. SARTOR O
    Invited Perspective, Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis.
    J Nucl Med. 2022 May 26. pii: jnumed.122.264128. doi: 10.2967/jnumed.122.264128.
    PubMed    


  28. DUAN H, Baratto L, Fan RE, Soerensen SJC, et al
    Correlation of (68)Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
    J Nucl Med. 2022 May 12. pii: jnumed.122.263971. doi: 10.2967/jnumed.122.263971.
    PubMed     Abstract available



  29. FDA Approves Pluvicto/Locametz for Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2022;63:13N.
    PubMed    


    April 2022
  30. DENIS CES, Cousin FC, De Laere B, Hustinx R, et al
    Using, (68)Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.
    J Nucl Med. 2022 Apr 21. pii: jnumed.121.263611. doi: 10.2967/jnumed.121.263611.
    PubMed     Abstract available


  31. GAFITA A, Rauscher I, Weber M, Hadaschik B, et al
    Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study.
    J Nucl Med. 2022 Apr 14. pii: jnumed.121.263072. doi: 10.2967/jnumed.121.263072.
    PubMed     Abstract available


  32. KROENKE M, Schweiger L, Horn T, Haller B, et al
    Validation of (18)F-rhPSMA-7 and (18)F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
    J Nucl Med. 2022 Apr 7. pii: jnumed.121.263707. doi: 10.2967/jnumed.121.263707.
    PubMed     Abstract available


    March 2022
  33. EMMETT LM, Papa N, Buteau J, Ho B, et al
    The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis.
    J Nucl Med. 2022 Mar 17. pii: jnumed.121.263448. doi: 10.2967/jnumed.121.263448.
    PubMed     Abstract available


  34. ILHAN H, Kroenke M, Wurzer A, Unterrainer M, et al
    (18)F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
    J Nucl Med. 2022 Mar 10. pii: jnumed.121.262861. doi: 10.2967/jnumed.121.262861.
    PubMed     Abstract available


  35. HOTTA M, Gafita A, Czernin J, Calais J, et al
    Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with (177)Lu-PSMA therapy: a multicenter retrospective analysis.
    J Nucl Med. 2022 Mar 10. pii: jnumed.121.263441. doi: 10.2967/jnumed.121.263441.
    PubMed     Abstract available


  36. NOTOHAMIPRODJO S, Eiber M, Lohrmann C, Weber WA, et al
    Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on (18)F-rhPSMA-7.3 PET/CT in patients with prostate cancer.
    J Nucl Med. 2022 Mar 3. pii: jnumed.121.263758. doi: 10.2967/jnumed.121.263758.
    PubMed     Abstract available


  37. GONDOPUTRO W, Scheltema MJ, Blazevski A, Doan P, et al
    Robot-assisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer.
    J Nucl Med. 2022 Mar 3. pii: jnumed.121.263743. doi: 10.2967/jnumed.121.263743.
    PubMed     Abstract available


    February 2022
  38. WU WY, Yu F, Zhang PJ, Bu T, et al
    (68)Ga-DOTA-NT-20.3 Neurotensin receptor 1 positron emission tomography imaging as a surrogate for neuroendocrine differentiation of prostate cancer.
    J Nucl Med. 2022 Feb 17. pii: jnumed.121.263132. doi: 10.2967/jnumed.121.263132.
    PubMed     Abstract available



  39. FDA Approves New (68)Ga Kit for Prostate Cancer PET.
    J Nucl Med. 2022;63:26N.
    PubMed    


  40. SARTOR O
    Reply: A VISION of ALSYMPCA.
    J Nucl Med. 2022;63:324-325.
    PubMed    


  41. SCHIAVOM DUARTE P
    A VISION of ALSYMPCA.
    J Nucl Med. 2022;63:324.
    PubMed    


  42. MEASE RC, Kang CM, Kumar V, Banerjee SR, et al
    An Improved (211)At-Labeled Agent for PSMA-Targeted alpha-Therapy.
    J Nucl Med. 2022;63:259-267.
    PubMed     Abstract available


    January 2022
  43. WURZER A, Kunert JP, Fischer S, Felber V, et al
    Synthesis and Preclinical Evaluation of (177)Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer.
    J Nucl Med. 2022 Jan 27. pii: jnumed.121.263371. doi: 10.2967/jnumed.121.263371.
    PubMed     Abstract available


  44. KORSEN JA, Kalidindi TM, Khitrov S, Samuels ZV, et al
    Molecular imaging of Neuroendocrine Prostate Cancer by targeting Delta-like Ligand 3.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263221. doi: 10.2967/jnumed.121.263221.
    PubMed     Abstract available


  45. SUTERA P, Phillips RM, Deek M, Ozyigit G, et al
    The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer - Going Beneath the Surface with Molecular Imaging.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263684. doi: 10.2967/jnumed.121.263684.
    PubMed    


  46. NG M, Guerrieri M, Wong LM, Taubman K, et al
    The change in management by (18)F-DCFPyL PSMA PET scanning in patients undergoing post-prostatectomy radiotherapy, with early biochemical response outcomes.
    J Nucl Med. 2022 Jan 20. pii: jnumed.121.263521. doi: 10.2967/jnumed.121.263521.
    PubMed     Abstract available


  47. LANGBEIN T, Wang H, Rauscher I, Kronke M, et al
    Utility of (18)F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
    J Nucl Med. 2022 Jan 6. pii: jnumed.121.263440. doi: 10.2967/jnumed.121.263440.
    PubMed     Abstract available


  48. CHEN R, Wang Y, Zhu Y, Shi Y, et al
    The Added Value of (18)F-FDG PET/CT Compared with (68)Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer.
    J Nucl Med. 2022;63:69-75.
    PubMed     Abstract available


    December 2021
  49. MENA E, Rowe SP, Shih JH, Lindenberg L, et al
    Predictors of (18)F-DCFPyL-PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.
    J Nucl Med. 2021 Dec 16. pii: jnumed.121.262347. doi: 10.2967/jnumed.121.262347.
    PubMed     Abstract available


  50. SCHUCHARDT C, Zhang J, Kulkarni HR, Chen X, et al
    Prostate-specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry.
    J Nucl Med. 2021 Dec 9. pii: jnumed.121.262713. doi: 10.2967/jnumed.121.262713.
    PubMed     Abstract available


    November 2021
  51. SHAGERA QA, Artigas C, Karfis I, Critchi G, et al
    (68)Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy.
    J Nucl Med. 2021 Nov 12. pii: jnumed.121.263006. doi: 10.2967/jnumed.121.263006.
    PubMed     Abstract available


  52. CALAIS J, Czernin J
    PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.
    J Nucl Med. 2021;62:1489-1491.
    PubMed    


  53. SRINIVAS S, Iagaru A
    To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy.
    J Nucl Med. 2021;62:1487-1488.
    PubMed    


    October 2021
  54. MIYAHIRA AK, Soule HR
    The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Foundational Role of the Prostate Cancer Foundation.
    J Nucl Med. 2021 Oct 21. pii: jnumed.121.262997. doi: 10.2967/jnumed.121.262997.
    PubMed     Abstract available


  55. SONNI I, Felker ER, Lenis AT, Sisk AE, et al
    Head-to-head comparison of (68)Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial.
    J Nucl Med. 2021 Oct 14. pii: jnumed.121.262398. doi: 10.2967/jnumed.121.262398.
    PubMed     Abstract available


  56. CALAIS J, Czernin J, Thin P, Gartmann J, et al
    Safety of PSMA-Targeted Molecular Radioligand Therapy with (177)Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312).
    J Nucl Med. 2021;62:1447-1456.
    PubMed     Abstract available


  57. NOTNI J
    PSMA-Targeted Therapeutics: A Tale About Law and Economics.
    J Nucl Med. 2021;62:1482.
    PubMed    


  58. EDER AC, Schafer M, Schmidt J, Bauder-Wust U, et al
    Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules.
    J Nucl Med. 2021;62:1461-1467.
    PubMed     Abstract available


    September 2021
  59. FEUERECKER B, Chantadisai M, Allmann A, Tauber R, et al
    Pre-therapeutic comparative dosimetry of (177)Lu-rhPSMA-7.3 and (177)Lu-PSMAI&T in patients with metastatic castration resistant prostate cancer (mCRPC).
    J Nucl Med. 2021 Sep 16. pii: jnumed.121.262671. doi: 10.2967/jnumed.121.262671.
    PubMed     Abstract available


  60. LEE DY, Kim YI
    Effects of (225)Ac-labeled prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer: A meta-analysis.
    J Nucl Med. 2021 Sep 9. pii: jnumed.121.262017. doi: 10.2967/jnumed.121.262017.
    PubMed     Abstract available


  61. FOURQUET A, Rosenberg A, Mena E, Shih JJ, et al
    A comparison of (18)F-DCFPyL, (18)F-NaF and (18)F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer.
    J Nucl Med. 2021 Sep 2. pii: jnumed.121.262371. doi: 10.2967/jnumed.121.262371.
    PubMed     Abstract available


  62. WAHL RL
    Progress in Prostate Cancer Theranostics.
    J Nucl Med. 2021;62:11N.
    PubMed    


  63. BRENNER W, Strobel J, Prasad V
    PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?
    J Nucl Med. 2021;62:1242-1243.
    PubMed    


    August 2021
  64. SEIFERT R, Sandach P, Kersting D, Fendler WP, et al
    Repeatability of (68)Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume.
    J Nucl Med. 2021 Aug 26. pii: jnumed.121.262528. doi: 10.2967/jnumed.121.262528.
    PubMed     Abstract available


  65. PARIHAR AS, Schmidt LR, Dehdashti F, Wahl RL, et al
    Detection of additional primary neoplasms on (18)F-Fluciclovine PET/CT in patients with primary prostate cancer.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262647. doi: 10.2967/jnumed.121.262647.
    PubMed     Abstract available


  66. SANDHU S, Guo C, Hofman MS
    Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics.
    J Nucl Med. 2021 Aug 12. pii: jnumed.120.243295. doi: 10.2967/jnumed.120.243295.
    PubMed     Abstract available


  67. LANGBEIN T, Wurzer A, Gafita A, Robertson A, et al
    The Influence of Specific Activity on the Biodistribution of (18)F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262471. doi: 10.2967/jnumed.121.262471.
    PubMed     Abstract available



  68. FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
    J Nucl Med. 2021;62:11N.
    PubMed    



  69. FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
    J Nucl Med. 2021;62:11N.
    PubMed    


  70. CZERNIN J, Calais J
    (177)Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.
    J Nucl Med. 2021;62:1025-1026.
    PubMed    


  71. YUSUFI N, Wurzer A, Herz M, D'Alessandria C, et al
    Comparative Preclinical Biodistribution, Dosimetry, and Endoradiotherapy in Metastatic Castration-Resistant Prostate Cancer Using (19)F/(177)Lu-rhPSMA-7.3 and (177)Lu-PSMA I&T.
    J Nucl Med. 2021;62:1106-1111.
    PubMed     Abstract available


  72. FERNANDEZ R, Eppard E, Lehnert W, Jimenez-Franco LD, et al
    Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases.
    J Nucl Med. 2021;62:1126-1132.
    PubMed     Abstract available


  73. URBAN S, Meyer C, Dahlbom M, Farkas I, et al
    Radiation Dosimetry of (99m)Tc-PSMA I&S: A Single-Center Prospective Study.
    J Nucl Med. 2021;62:1075-1081.
    PubMed     Abstract available


    July 2021
  74. DIETLEIN F, Kobe C, Munoz Vazquez S, Fischer T, et al
    An (89)Zr-labeled PSMA tracer for PET/CT imaging of prostate cancer patients.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262290. doi: 10.2967/jnumed.121.262290.
    PubMed     Abstract available


  75. DONG L, Su Y, Zhu Y, Markowski MC, et al
    The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262411. doi: 10.2967/jnumed.121.262411.
    PubMed     Abstract available


  76. PATHMANANDAVEL S, Crumbaker M, Yam AO, Nguyen A, et al
    (177)Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262552. doi: 10.2967/jnumed.121.262552.
    PubMed     Abstract available


  77. ABGHARI-GERST M, Armstrong WR, Nguyen K, Calais J, et al
    A comprehensive assessment of (68)Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262412. doi: 10.2967/jnumed.121.262412.
    PubMed     Abstract available


  78. BENARD F, Bratanovic IJ
    A Novel Radiotracer for Molecular Imaging and Therapy of Gastrin-Releasing Peptide Receptor Positive Prostate Cancer.
    J Nucl Med. 2021 Jul 22. pii: jnumed.120.257758. doi: 10.2967/jnumed.120.257758.
    PubMed     Abstract available


  79. CERCI JJ, Fanti S, Lobato EE, Kunikowska J, et al
    Diagnostic performance and clinical impact of (68)Ga-PSMA-11 imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA study).
    J Nucl Med. 2021 Jul 2. pii: jnumed.120.261886. doi: 10.2967/jnumed.120.261886.
    PubMed     Abstract available


    June 2021
  80. SARTOR AO, la Fougere C, Essler M, Ezziddin S, et al
    Lutetium-177-prostate-specific membrane antigen ligand following radium-223 treatment in men with bone-metastatic castration-resistant prostate cancer: real-world clinical experience.
    J Nucl Med. 2021 Jun 24. pii: jnumed.121.262240. doi: 10.2967/jnumed.121.262240.
    PubMed     Abstract available


  81. MIX M, Renaud T, Kind F, Nemer U, et al
    Kidney doses in (177)Lu-based radioligand therapy in prostate cancer: Is dose estimation based on reduced dosimetry measurements feasible?
    J Nucl Med. 2021 Jun 4. pii: jnumed.121.262245. doi: 10.2967/jnumed.121.262245.
    PubMed     Abstract available


  82. MCINNES LE, Cullinane C, Roselt PD, Jackson S, et al
    Therapeutic Efficacy of a Bivalent Inhibitor of Prostate-Specific Membrane Antigen Labeled with (67)Cu.
    J Nucl Med. 2021;62:829-832.
    PubMed     Abstract available


    May 2021
  83. NICKOLS N, Anand A, Johnsson K, Brynolfsson J, et al
    aPROMISE: A Novel Automated-PROMISE platform to Standardize Evaluation of Tumor Burden in (18)F-DCFPyL (PSMA) images of Veterans with Prostate Cancer.
    J Nucl Med. 2021 May 28. pii: jnumed.120.261863. doi: 10.2967/jnumed.120.261863.
    PubMed     Abstract available


  84. GAFITA A, Wang H, Robertson A, Armstrong WR, et al
    Tumor sink effect in (68)Ga-PSMA-11 PET: Myth or Reality?
    J Nucl Med. 2021 May 28. pii: jnumed.121.261906. doi: 10.2967/jnumed.121.261906.
    PubMed     Abstract available


  85. CALAIS J, Gafita A, Eiber MR, Armstrong WR, et al
    Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with (177)Lu-PSMA-617 for metastatic Castration-reSISTant Prostate Cancer (RESIST-PC): Efficacy results of the UCLA cohort.
    J Nucl Med. 2021 May 20. pii: jnumed.121.261982. doi: 10.2967/jnumed.121.261982.
    PubMed     Abstract available


  86. BARBATO F, Fendler WP, Rauscher I, Herrmann K, et al
    PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease.
    J Nucl Med. 2021 May 14. pii: jnumed.121.262120. doi: 10.2967/jnumed.121.262120.
    PubMed     Abstract available


  87. TREIBER H, Koenig A, Neesse A, Richter A, et al
    Liver enzyme elevation after (177)Lu-PSMA radioligand therapy for metastasized castration-resistant prostate cancer.
    J Nucl Med. 2021 May 14. pii: jnumed.120.258533. doi: 10.2967/jnumed.120.258533.
    PubMed     Abstract available


  88. ZACHERL MJ, Gildehaus FJ, Mittlmeier L, Boning G, et al
    First Clinical Results for PSMA-Targeted alpha-Therapy Using (225)Ac-PSMA-I&T in Advanced-mCRPC Patients.
    J Nucl Med. 2021;62:669-674.
    PubMed     Abstract available


    April 2021
  89. FENDLER WP, Farolfi A
    REPLY: The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer.
    J Nucl Med. 2021 Apr 30. pii: jnumed.121.262271. doi: 10.2967/jnumed.121.262271.
    PubMed    


  90. OLDE HEUVEL J, de Wit-van der Veen BJ, van der Poel HG, van Leeuwen PJ, et al
    Cerenkov Luminescence Imaging in prostate cancer: not the only light that shines.
    J Nucl Med. 2021 Apr 30. pii: jnumed.120.260034. doi: 10.2967/jnumed.120.260034.
    PubMed     Abstract available


  91. CHEN R, Wang Y, Zhu Y, Shi Y, et al
    The added value of (18)F-FDG PET/CT compared to (68)Ga-PSMA PET/CT in patients with castration-resistant prostate cancer.
    J Nucl Med. 2021 Apr 23. pii: jnumed.121.262250. doi: 10.2967/jnumed.121.262250.
    PubMed     Abstract available


  92. BRAVI CA, Fossati N, Gandaglia G, Suardi N, et al
    The importance of an adequate surgical template during salvage lymph node dissection for node-recurrent prostate cancer.
    J Nucl Med. 2021 Apr 16. pii: jnumed.121.262104. doi: 10.2967/jnumed.121.262104.
    PubMed    


    March 2021
  93. RITT P, Jobic C, Beck M, Schmidkonz C, et al
    Dissimilar DNA Damage to Blood Lymphocytes After (177)Lu-Labeled DOTATOC or Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2021;62:379-385.
    PubMed     Abstract available


    November 2020
  94. MEIJER D, Donswijk ML, Bodar YJL, van Leeuwen PJ, et al
    Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging.
    J Nucl Med. 2020 Nov 6. pii: jnumed.120.252528. doi: 10.2967/jnumed.120.252528.
    PubMed     Abstract available


    October 2020
  95. LODGE MA, Lesniak W, Gorin MA, Pienta KJ, et al
    Measurement of PET Quantitative Bias In Vivo.
    J Nucl Med. 2020 Oct 9. pii: jnumed.120.251397. doi: 10.2967/jnumed.120.251397.
    PubMed     Abstract available


    September 2020
  96. FAROLFI A, Hirmas N, Gafita A, Weber M, et al
    PSMA-PET identifies PCWG3 target populations with superior accuracy and reproducibility when compared to conventional imaging: a multicenter retrospective study.
    J Nucl Med. 2020 Sep 11. pii: jnumed.120.246603. doi: 10.2967/jnumed.120.246603.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: